NCT07078929View on ClinicalTrials.gov

Phase I Clinical Trial of CMD63 CAR T Cell in Children With Acute Lymphoblastic Leukemia

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2028

Conditions
Relapse B Acute Lymphoblastic LeukemiaRefactory Childhood Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

CD19-IL7Ra CAR-T cells

Autologous T cells lentiviral transduced to express a CD19-specific chimeric antigen receptor (CAR) with the addition of an IL-7 receptor alpha signaling domain, administered via central venous access catheter after lymphodepletion

Trial Locations (1)

10330

King Chulalongkorn Memorial Hospital, Bangkok

All Listed Sponsors
collaborator

King Chulalongkorn Memorial Hospital

OTHER

lead

Chulalongkorn University

OTHER